The impact of allergic rhinitis on sleep is real

The impact of allergic rhinitis on sleep is real

Allergic rhinitis affects sleep

Allergic rhinitis has a real impact on patients1 sleep and general well-being.1

Patients suffering from moderate-severe allergic rhinitis have reported the following:

  • Not feeling rested on waking effects 52% of persistent allergic rhinitis sufferers and 35% of intermittent sufferers.1
  • Disturbed sleep effects 49% of persistent allergic rhinitis sufferers and 35% of intermittent sufferers.1
  • Difficulty getting to sleep effects 32% of persistent allergic rhinitis sufferers and 24% of intermittent sufferers.1
dymista

Allergic rhinitis impacts patients’ sleep and well-being13

  • Slide
Click to download full slide deck

Further Your Understanding

Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.

  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
    Onset
  • Impact
    Treatment
  • Guidelines
    Guidelines
  • Clinical Papers
    Clinical Papers

References

  1. National Institute of Heatth and Care Excellence (NICE). Clinical knowledge summary: Allergic rhinitis. October 2015. Available at: https://cks.nice.org.uk/allergic-rhinitis#!topicsummary.
  2. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62(Suppl 85): 17-25.

Want to expand your knowledge?

Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.

Mylan Connects

Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.

REGISTER NOW

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk


This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.​

Copyright © 2023 Viatris Inc All rights reserved. Dymista® is a registered trademark of Viatris Inc.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo